chemotherapy of tuberculosis
DESCRIPTION
Chemotherapy of Tuberculosis. Tuberculosis. Chronic granulomatous disease. Usually affects the lungs, up to one third of cases, other organs are involved. Etiologic agent. Mycobacterium causes: Tuberculosis Mycobacterium avium complex disease Leprosy. - PowerPoint PPT PresentationTRANSCRIPT
![Page 1: Chemotherapy of Tuberculosis](https://reader034.vdocuments.net/reader034/viewer/2022051518/568155e4550346895dc3ac07/html5/thumbnails/1.jpg)
Chemotherapy of Tuberculosis
![Page 2: Chemotherapy of Tuberculosis](https://reader034.vdocuments.net/reader034/viewer/2022051518/568155e4550346895dc3ac07/html5/thumbnails/2.jpg)
Tuberculosis
Chronic granulomatous disease.
Usually affects the lungs, up to one third of cases, other organs are involved.
![Page 3: Chemotherapy of Tuberculosis](https://reader034.vdocuments.net/reader034/viewer/2022051518/568155e4550346895dc3ac07/html5/thumbnails/3.jpg)
Etiologic agent
Mycobacterium causes: Tuberculosis Mycobacterium avium complex disease Leprosy
![Page 4: Chemotherapy of Tuberculosis](https://reader034.vdocuments.net/reader034/viewer/2022051518/568155e4550346895dc3ac07/html5/thumbnails/4.jpg)
Mycobacterium tuberculosis complex:
Mycobacterium tuberculosis : Rod shaped, non- pore-forming, thin aerobic
bacterium. Important agent for human disease.
M. bovis Important cause of tuberculosis for transmitted
by unpasteurised milk. M . africanum
West, central & east africa. M .microti
Less virulent, rarely encountered organism.
![Page 5: Chemotherapy of Tuberculosis](https://reader034.vdocuments.net/reader034/viewer/2022051518/568155e4550346895dc3ac07/html5/thumbnails/5.jpg)
M.tuberculosis transmitted from patient with infectious pulmonary Tb to other persons
By droplet nuclei, Aerosolised by coughing, sneezing or speaking.
As many as 3000 infectious nuclei per cough.
![Page 6: Chemotherapy of Tuberculosis](https://reader034.vdocuments.net/reader034/viewer/2022051518/568155e4550346895dc3ac07/html5/thumbnails/6.jpg)
Tiny droplets dry rapidly. Smallest droplets (<10 um in diameter)
Suspended in the air for several hours , May gain direct access to the terminal air
passages when inhaled.
![Page 7: Chemotherapy of Tuberculosis](https://reader034.vdocuments.net/reader034/viewer/2022051518/568155e4550346895dc3ac07/html5/thumbnails/7.jpg)
Risk factors for acquiring infection with M.Tuberculosis:
Probability of contact with the case of Tb.Intimacy and duration of that contact.Degree of infectiousness of the case.Shared environment of the contact.
![Page 8: Chemotherapy of Tuberculosis](https://reader034.vdocuments.net/reader034/viewer/2022051518/568155e4550346895dc3ac07/html5/thumbnails/8.jpg)
Risk factor for developing disease after being infected :
Individuals innate susceptibility to disease.Level of function of cell mediated immunity.
![Page 9: Chemotherapy of Tuberculosis](https://reader034.vdocuments.net/reader034/viewer/2022051518/568155e4550346895dc3ac07/html5/thumbnails/9.jpg)
Clinical manifestations Pulmonary Tb
Primary Secondary
Extra pulmonary Tb Lymph node Tb Pleural Tb Tb of upper airways Genitourinary Tb Skeletal Tb Tuberculous meningitis Gastrointestinal Tb Pericardial Tb Miliary / disseminated Tb
![Page 10: Chemotherapy of Tuberculosis](https://reader034.vdocuments.net/reader034/viewer/2022051518/568155e4550346895dc3ac07/html5/thumbnails/10.jpg)
Primary Tuberculosis Results from initial
infection with tubercle bacilli.
Children up to 4 yrs of age.
Middle, lower lung zone affected mainly.
Rapid progression to illness in HIV patients.
![Page 11: Chemotherapy of Tuberculosis](https://reader034.vdocuments.net/reader034/viewer/2022051518/568155e4550346895dc3ac07/html5/thumbnails/11.jpg)
Pleural effusion: due to penetration of bacilli into pleural space
from subsequent subpleural area. Lymphadenopathy:
due to spread of bacilli from lung parenchyma through lymphatic vessel.
Obstruction & subsequent segmental collapse: as enlarged lymph node compress bronchi.
Obstructive emphysema: due to partial obstruction.
Granulomatous lesions: seen in severe cases as bacilli reach blood
stream from pulmonary lesion/lymph nodes
![Page 12: Chemotherapy of Tuberculosis](https://reader034.vdocuments.net/reader034/viewer/2022051518/568155e4550346895dc3ac07/html5/thumbnails/12.jpg)
Secondary Tuberculosis
Adult type. Dormant bacilli, may persist for years before
reactivating to produce Secondary Tuberculosis- often infectious.
Localised to the apical & posterior segments of the upper lobes , where high oxygen concentration favours mycobacterial growth.
![Page 13: Chemotherapy of Tuberculosis](https://reader034.vdocuments.net/reader034/viewer/2022051518/568155e4550346895dc3ac07/html5/thumbnails/13.jpg)
Secondary Tb.....
Early symptoms: fever, night sweats, weight loss, malaise, weakness.
Development of Cough : non productive initially, production of purulent sputum.
![Page 14: Chemotherapy of Tuberculosis](https://reader034.vdocuments.net/reader034/viewer/2022051518/568155e4550346895dc3ac07/html5/thumbnails/14.jpg)
Diagnosis of Tuberculosis AFB (Acid Fast Bacilli) microscopy Presumptive diagnosis.
Mycobacterial culture Definitive diagnosis
Nucleic acid amplification Use limited due to low sensitivity.
Drug susceptibility testing To find out drug resistance.
Radiographic procedure Based on abnormal chest radiographic findings
Tuberculin skin testing Lack of mycobacterial specificity limits use
Cytokine release assay Diagnosis of latent tuberculosis infection.
![Page 15: Chemotherapy of Tuberculosis](https://reader034.vdocuments.net/reader034/viewer/2022051518/568155e4550346895dc3ac07/html5/thumbnails/15.jpg)
Treatment
Aim of treating Tuberculosis:To interrupt tuberculosis transmission by rendering patients non-infectious.To prevent morbidity & mortality by curing patients with tuberculosis disease.
![Page 16: Chemotherapy of Tuberculosis](https://reader034.vdocuments.net/reader034/viewer/2022051518/568155e4550346895dc3ac07/html5/thumbnails/16.jpg)
Antitubercular drugs
First line drugs : High efficacy & low toxicity.
Isoniazid 5mg / kg /d , max of 300 mg / d Rifampin 10 mg/kg/d, max of 600 mg / d Pyrazinamide 20-25 mg/kg/d, max of 2g / d Ethambutol 15 -20 mg / kg / d Streptomycin 15 mg / kg / d
![Page 17: Chemotherapy of Tuberculosis](https://reader034.vdocuments.net/reader034/viewer/2022051518/568155e4550346895dc3ac07/html5/thumbnails/17.jpg)
Second line agentsEither low efficacy or high toxicity or both Slide 76
Drugs Drugs Doses Doses Amikacin 15 mg/kg/d
Aminosalicylic acid 8-12 g/d
Capreomycin 15 mg/kg/d
Ciprofloxacin 1500 mg/kg/d
Clofazimine 200 mg/d
Cycloserine 500-1000 mg/d
Ethionamide 500-750 mg/d
Levofloxacin 500 mg/d
Rifabutin 300 mg/d
Rifapentine 600 mg o.d weekly
![Page 18: Chemotherapy of Tuberculosis](https://reader034.vdocuments.net/reader034/viewer/2022051518/568155e4550346895dc3ac07/html5/thumbnails/18.jpg)
Isoniazid
Bacteriostatic for resting bacilli but bactericidal for rapidly dividing micro-organisms.
Minimal effective conc.: 0.025-0.05 ug/ml. Peak plasma conc. : 1-2 hrs. Good oral & parenteral absorption.
![Page 19: Chemotherapy of Tuberculosis](https://reader034.vdocuments.net/reader034/viewer/2022051518/568155e4550346895dc3ac07/html5/thumbnails/19.jpg)
Metabolism
via acetylation
(acetylisoniazid)
& via hydrolysis
(isonicotinic
acid).
![Page 20: Chemotherapy of Tuberculosis](https://reader034.vdocuments.net/reader034/viewer/2022051518/568155e4550346895dc3ac07/html5/thumbnails/20.jpg)
N-acetyltransferase type 2 (NAT 2)
Fast acetylators Slow acetylators
t½ of INH =1hr t½ of INH =2-5 hrs
Hepatic insufficiency In case of renal impairment, may accumulate to toxic
concentration.
Dosage reduction recommended
![Page 21: Chemotherapy of Tuberculosis](https://reader034.vdocuments.net/reader034/viewer/2022051518/568155e4550346895dc3ac07/html5/thumbnails/21.jpg)
MECHANISM OF ACTION….INH
![Page 22: Chemotherapy of Tuberculosis](https://reader034.vdocuments.net/reader034/viewer/2022051518/568155e4550346895dc3ac07/html5/thumbnails/22.jpg)
![Page 23: Chemotherapy of Tuberculosis](https://reader034.vdocuments.net/reader034/viewer/2022051518/568155e4550346895dc3ac07/html5/thumbnails/23.jpg)
Resistance
1. Mutation in catalase peroxidase Decreases its activity Prevent conversion of prodrug to active
metabolite.
2. Mutation in inh A gene involved in mycolic acid biosynthesis. Resulting in over expression of inh A.
![Page 24: Chemotherapy of Tuberculosis](https://reader034.vdocuments.net/reader034/viewer/2022051518/568155e4550346895dc3ac07/html5/thumbnails/24.jpg)
Tuberculous cavity contains 109 micro-organism.
1 in 106 bacilli genetically resistant to INH.So, resistant mutants selected out in INH monotherapy.
![Page 25: Chemotherapy of Tuberculosis](https://reader034.vdocuments.net/reader034/viewer/2022051518/568155e4550346895dc3ac07/html5/thumbnails/25.jpg)
Adverse effects
INH induced hepatotoxicity. Peripheral neuropathy. Neurotoxicity. Hematological reactions. Hypersensitivity reactions.
![Page 26: Chemotherapy of Tuberculosis](https://reader034.vdocuments.net/reader034/viewer/2022051518/568155e4550346895dc3ac07/html5/thumbnails/26.jpg)
• INH induced hepatotoxicity.• Multilobular necrosis – by liver biopsy. • Risk factor :
• Older age & excessive alcohol intake.• <20 years: Rare• 35-49 years & >50 years: elevated serum transaminase
level.• > 5 times serum transaminase level: DISCONTINUE
Drug.
![Page 27: Chemotherapy of Tuberculosis](https://reader034.vdocuments.net/reader034/viewer/2022051518/568155e4550346895dc3ac07/html5/thumbnails/27.jpg)
Peripheral neuropathy: • Due to interference with utilization of
pyridoxine and its increased excretion in urine.
• Paresthesia of feet & hands. • Pyridoxine 10 mg/d for treatment.
![Page 28: Chemotherapy of Tuberculosis](https://reader034.vdocuments.net/reader034/viewer/2022051518/568155e4550346895dc3ac07/html5/thumbnails/28.jpg)
Neurotoxicity:• Convulsion , in patients with seizure disorder.• Optic neuropathy. • Muscle twitching, stupor.
![Page 29: Chemotherapy of Tuberculosis](https://reader034.vdocuments.net/reader034/viewer/2022051518/568155e4550346895dc3ac07/html5/thumbnails/29.jpg)
Hematological reaction: • Agranulocytosis, eosinophilia,
thrombocytopenia.• Sideroblastic anemia (presence of ring sideroblasts in
the bone marrow)
• Reversible .• INH deprives ALAS2 (delta-aminolaevulinic acid synthase 2) of
pyridoxal phosphate therefore inhibits haem synthesis.
• Overcome by concomitant administration of pyridoxine(25 to 50 mg/d).
![Page 30: Chemotherapy of Tuberculosis](https://reader034.vdocuments.net/reader034/viewer/2022051518/568155e4550346895dc3ac07/html5/thumbnails/30.jpg)
Hypersensitivity reaction:• Fever, rashes, hepatitis , SLE.INH overdose:• Tonic - clonic seizure, , metabolic acidosis, ,
coma in pregnant women. . • Pyridoxine – specific antidote.
![Page 31: Chemotherapy of Tuberculosis](https://reader034.vdocuments.net/reader034/viewer/2022051518/568155e4550346895dc3ac07/html5/thumbnails/31.jpg)
• Management :• GI decontamination with gastric lavage,• Stabilization of vital signs with provision of
patent airway and IV sodium bicarbonate,• Cardiovascular support with IV fluids and
vasopressors. • IV pyridoxine – highly effective for INH
intoxication and should be administered to all symptomatic patients.
![Page 32: Chemotherapy of Tuberculosis](https://reader034.vdocuments.net/reader034/viewer/2022051518/568155e4550346895dc3ac07/html5/thumbnails/32.jpg)
Uses of INH
Latent TbRecent converters: who test positive within 2 years after a documented negative skin test. Immunocompromised patients.Prevention, in close contacts of active cases of pulmonary Tb.
![Page 33: Chemotherapy of Tuberculosis](https://reader034.vdocuments.net/reader034/viewer/2022051518/568155e4550346895dc3ac07/html5/thumbnails/33.jpg)
INH ᵡ Phenytoin • Effect :
• Increased serum phenytoin level.• Slow acetylators – Phenytoin toxicity.
• Mode : • INH – hepatic microsomal enzyme inhibitor.
• Monitoring: • Need to monitor serum phenytoin level.
![Page 34: Chemotherapy of Tuberculosis](https://reader034.vdocuments.net/reader034/viewer/2022051518/568155e4550346895dc3ac07/html5/thumbnails/34.jpg)
INH ᵡ Rifampin
• Effect: • Hepatotoxicity.
• Mode: • Altered INH metabolism by rifampin.
• Monitoring:• If LFT alter, discontinue one or both agents.
![Page 35: Chemotherapy of Tuberculosis](https://reader034.vdocuments.net/reader034/viewer/2022051518/568155e4550346895dc3ac07/html5/thumbnails/35.jpg)
Rifamycins
Rifampin
Rifabutin
Rifapentine
![Page 36: Chemotherapy of Tuberculosis](https://reader034.vdocuments.net/reader034/viewer/2022051518/568155e4550346895dc3ac07/html5/thumbnails/36.jpg)
Mechanism of action:
Bactericidal at 3-12 ng/ml for both
intracellular & extracellular microorganisms.
Kills organisms at poorly accessible sites like
abscess, lung cavities.
![Page 37: Chemotherapy of Tuberculosis](https://reader034.vdocuments.net/reader034/viewer/2022051518/568155e4550346895dc3ac07/html5/thumbnails/37.jpg)
Binds to β subunit of bacterial DNA dependent RNA polymerase.
Suppression of initiation of chain formation but no chain elongation in RNA synthesis.
Inhibit RNA synthesis in mammalian mitochondria, viral DNA dependent RNA
Polymerase, reverse transcriptase at high concentration.
![Page 38: Chemotherapy of Tuberculosis](https://reader034.vdocuments.net/reader034/viewer/2022051518/568155e4550346895dc3ac07/html5/thumbnails/38.jpg)
Mechanism of resistance
1. Mutation between codons 507 & 533 of polymerase rpo B gene “for β subunit of RNA polymerase. Prevent binding of rifampin to RNA polymerase.
2. Alterations in the target of drug: DNA dependent RNA polymerase.
![Page 39: Chemotherapy of Tuberculosis](https://reader034.vdocuments.net/reader034/viewer/2022051518/568155e4550346895dc3ac07/html5/thumbnails/39.jpg)
Adverse effects Hepatitis from rifampin rarely occurs in patients with normal hepatic function.Chronic liver disease, alcoholism, and old age increase the risk of severe hepatitis when rifampin is given alone or concurrently with isoniazid.< 5% of patients, serum level of aminotransferase, phosphatase, bilirubin increase slightly, but diminish spontaneously despite continuation of treatment.
![Page 40: Chemotherapy of Tuberculosis](https://reader034.vdocuments.net/reader034/viewer/2022051518/568155e4550346895dc3ac07/html5/thumbnails/40.jpg)
Rifampin may potentiate toxic effect of INH, particularly in patients in whom INH is rapidly inactivated.
Rifampin induces microsomal enzyme. Facilitate conversion of monoacetylhydrazine,
a metabolite of acetylated INH into an acylating agent that could cause hepatic
necrosis.
![Page 41: Chemotherapy of Tuberculosis](https://reader034.vdocuments.net/reader034/viewer/2022051518/568155e4550346895dc3ac07/html5/thumbnails/41.jpg)
Light chain proteinuria. Imparts a harmless orange colour to urine, sweat, tears, and contact lenses (soft lenses may be permanently stained)
![Page 42: Chemotherapy of Tuberculosis](https://reader034.vdocuments.net/reader034/viewer/2022051518/568155e4550346895dc3ac07/html5/thumbnails/42.jpg)
GI disturbances –(epigastric distress, nausea, vomiting, abdominal cramps, diarrhea) occasionally required drug discontinuation.Thrombocytopenia, transient leukopenia, and anaemia have occurred during therapy.
![Page 43: Chemotherapy of Tuberculosis](https://reader034.vdocuments.net/reader034/viewer/2022051518/568155e4550346895dc3ac07/html5/thumbnails/43.jpg)
Rifampin × Anticoagulants EFFECT :
Decreased anticoagulant effect. MECHANISM:
Rifampin induces CYP2C9, CYP2C19, CYP2D6 Increases elimination of other drug.
MONITORING: Carefully monitor coagulation parameter.
Adjust anticoagulant dose.
![Page 44: Chemotherapy of Tuberculosis](https://reader034.vdocuments.net/reader034/viewer/2022051518/568155e4550346895dc3ac07/html5/thumbnails/44.jpg)
Ethambutol
Inhibit mycobacterial arabinosyl transferases,
which is involved in polymerization reaction of
arabinoglycan …….essential component of
mycobacterial cell wall.
![Page 45: Chemotherapy of Tuberculosis](https://reader034.vdocuments.net/reader034/viewer/2022051518/568155e4550346895dc3ac07/html5/thumbnails/45.jpg)
Adv. : Retrobulbar neuritis causing loss of visual
acuity and red-green colour blindness. (Serious).
Not recommended for children under 5 years of age because of concern about the ability to test their visual acuity.
![Page 46: Chemotherapy of Tuberculosis](https://reader034.vdocuments.net/reader034/viewer/2022051518/568155e4550346895dc3ac07/html5/thumbnails/46.jpg)
Pyrazinamide
PRODRUG Pyrazinoic acid pyrazinamidase (ACTIVE FORM)
encoded by pnc A
BACTERICIDALImpaired mutation
of pnc A
RESISTANCE
![Page 47: Chemotherapy of Tuberculosis](https://reader034.vdocuments.net/reader034/viewer/2022051518/568155e4550346895dc3ac07/html5/thumbnails/47.jpg)
Hepatotoxicity (in 1–5% of patients), nausea,
vomiting, drug fever, and hyperuricemia.
Hyperuricemia may provoke acute gouty
arthritis.
![Page 48: Chemotherapy of Tuberculosis](https://reader034.vdocuments.net/reader034/viewer/2022051518/568155e4550346895dc3ac07/html5/thumbnails/48.jpg)
Streptomycin Binds with S12 ribosomal protein.
Interfere with initiation of peptide formation. Misreading of mRNA. Breakup of polysomes into nonfunctional
monosomes.
Irreversible inhibition of mycobacterial protein synthesis.
![Page 49: Chemotherapy of Tuberculosis](https://reader034.vdocuments.net/reader034/viewer/2022051518/568155e4550346895dc3ac07/html5/thumbnails/49.jpg)
Ototoxic and nephrotoxic.(8th cranial nerve involves).
Vertigo and hearing loss -most common. may be permanent.
![Page 50: Chemotherapy of Tuberculosis](https://reader034.vdocuments.net/reader034/viewer/2022051518/568155e4550346895dc3ac07/html5/thumbnails/50.jpg)
Ethionamide
Inhibits mycobacterial growth by inhibiting the activity of the enoyl-ACP reductase of fatty acid synthase II.
Thus inhibit mycolic acid biosynthesis with consequent impairment of cell-wall synthesis.
![Page 51: Chemotherapy of Tuberculosis](https://reader034.vdocuments.net/reader034/viewer/2022051518/568155e4550346895dc3ac07/html5/thumbnails/51.jpg)
Neurologic symptoms – depression, drowsiness, and asthenia.olfactory disturbances, blurred vision,
diplopia, dizziness, paresthesias, headache, restlessness, and tremors.
Pyridoxine relieves.
![Page 52: Chemotherapy of Tuberculosis](https://reader034.vdocuments.net/reader034/viewer/2022051518/568155e4550346895dc3ac07/html5/thumbnails/52.jpg)
Chemoprophylaxis
To prevent development of active TB in patients who are at risk.
Tuberculin skin test ȳ interferon test
Mantoux test T-Spot.Tb
Heaf test QuantiFeron Tb Gold
Tine test
![Page 53: Chemotherapy of Tuberculosis](https://reader034.vdocuments.net/reader034/viewer/2022051518/568155e4550346895dc3ac07/html5/thumbnails/53.jpg)
Indications for chemoprophylaxis:1. New born of a mother with active TB.2. Young children (<6 yrs.) with positive TB.3. Household contacts of patients with TB.4. Patients with positive tuberculin test with
additional risk factors such as diabetes mellitus, malignancy, AIDS.
![Page 54: Chemotherapy of Tuberculosis](https://reader034.vdocuments.net/reader034/viewer/2022051518/568155e4550346895dc3ac07/html5/thumbnails/54.jpg)
Isoniazid prophylaxis, continued for 12
months. Pyridoxine co-administered.
HIV infected, exposed to MDRTb –
rifampin + pyrazinamide (with close
monitoring for hepatic toxicity) or high-dose
ethambutol +pyrazinamide, with or without a
fluoroquinolone.
![Page 55: Chemotherapy of Tuberculosis](https://reader034.vdocuments.net/reader034/viewer/2022051518/568155e4550346895dc3ac07/html5/thumbnails/55.jpg)
FOUR drug regimen treatment for whom?
![Page 56: Chemotherapy of Tuberculosis](https://reader034.vdocuments.net/reader034/viewer/2022051518/568155e4550346895dc3ac07/html5/thumbnails/56.jpg)
1. Known to exposed to drug resistant organisms.
2. Recent immigrants.3. Pts with extrapulmonary TB.4. Pts with meningitis.5. HIV pts.
![Page 57: Chemotherapy of Tuberculosis](https://reader034.vdocuments.net/reader034/viewer/2022051518/568155e4550346895dc3ac07/html5/thumbnails/57.jpg)
Continued for atleast 6 months after three
negative cultures obtained.
![Page 58: Chemotherapy of Tuberculosis](https://reader034.vdocuments.net/reader034/viewer/2022051518/568155e4550346895dc3ac07/html5/thumbnails/58.jpg)
MDTObjectives:
1. To make patient non-infectious as early as possible by rapidly killing the dividing bacilli by using 3 to 4 bactericidal drugs.
2. To prevent the development of drug-resistant bacilli.
3. To prevent relapse by killing the persisters (dormant bacilli).
4. To reduce the total duration of effective therapy.
![Page 59: Chemotherapy of Tuberculosis](https://reader034.vdocuments.net/reader034/viewer/2022051518/568155e4550346895dc3ac07/html5/thumbnails/59.jpg)
Recommended by WHO.Choice of treatment regimen based on:
Their efficacy, effectiveness, availability of financial recourses.
![Page 60: Chemotherapy of Tuberculosis](https://reader034.vdocuments.net/reader034/viewer/2022051518/568155e4550346895dc3ac07/html5/thumbnails/60.jpg)
Long course regimens:INH alone with one or two bacteriostatic drugs for 18 months.
Poor patient compliance, high failure rate.
![Page 61: Chemotherapy of Tuberculosis](https://reader034.vdocuments.net/reader034/viewer/2022051518/568155e4550346895dc3ac07/html5/thumbnails/61.jpg)
Short course regimen:6-9 months duration.Highly effective.Less toxic.
![Page 62: Chemotherapy of Tuberculosis](https://reader034.vdocuments.net/reader034/viewer/2022051518/568155e4550346895dc3ac07/html5/thumbnails/62.jpg)
Intensive phase:
- 3-4 tuberculocidal drugs daily or thrice weekly for a period of 2-3 months. - To render the patient non-contagious.
INH 300mg + Rifampicin 600 mg + Pyrazinamide 1500 mg + Ethambutol 1000 mg/Streptomycin 1000 mg + Pyridoxine 10 mg daily for 2 months.
![Page 63: Chemotherapy of Tuberculosis](https://reader034.vdocuments.net/reader034/viewer/2022051518/568155e4550346895dc3ac07/html5/thumbnails/63.jpg)
Continuous phase:
- 2-3 drugs usually INH & Rifampicin daily or thrice weekly for a period of
4-6 months. - Helps to eliminate persisters &
prevents relapse.
- INH 300mg +Pyridoxine 10 mg + Rifampicin 600 mg daily for 4
months.
![Page 64: Chemotherapy of Tuberculosis](https://reader034.vdocuments.net/reader034/viewer/2022051518/568155e4550346895dc3ac07/html5/thumbnails/64.jpg)
DOTS …. Backbone of RNTCP
![Page 65: Chemotherapy of Tuberculosis](https://reader034.vdocuments.net/reader034/viewer/2022051518/568155e4550346895dc3ac07/html5/thumbnails/65.jpg)
RNTCP:Revised National Tuberculosis Control Programme, launched in 1997
DOTS:Directly observed treatment short course.
![Page 66: Chemotherapy of Tuberculosis](https://reader034.vdocuments.net/reader034/viewer/2022051518/568155e4550346895dc3ac07/html5/thumbnails/66.jpg)
Patient is administered drugs under the supervision of a health worker to ensure that drugs are actually consumed.
Supervised and monitored by bacteriological examinations.
Aimed at ensuring patient compliance thus preventing the emergence of drug resistant tuberculosis.
![Page 67: Chemotherapy of Tuberculosis](https://reader034.vdocuments.net/reader034/viewer/2022051518/568155e4550346895dc3ac07/html5/thumbnails/67.jpg)
WHO recommended treatment regimen
Diagnostic category
Type of patient Intensive phase
Continuation phase
Total duration (months)
Category 1 New sputum positive, seriously ill sputum negative, seriously ill extrapulmonary
Daily 2HRZEThrice weekly 2 (HRZE)3
4HR
4(HR)3
6
6
Category 2 Sputum positive relapse, sputum positive treatment
Daily 2HRZES1HRZE
Thrice weekly2(HRZES)3
1(HRZE)3
5 HRE
5(HRE)3
8
8
![Page 68: Chemotherapy of Tuberculosis](https://reader034.vdocuments.net/reader034/viewer/2022051518/568155e4550346895dc3ac07/html5/thumbnails/68.jpg)
H=isoniazid, R=Rifampicin, Z=Pyrazinamide, E=Ethambutol, S=Streptomycin HRZ & E= orally ; S= i.m Prefix= number of months, Subscript= doses per week.
Diagnostic category
Type of patient Intensive phase
Continuation phase
Total duration (months)
Category 3 Sputum negative, not seriously ill, extrapulmonary, not seriously ill
Daily 2 HRT
Thrice weekly2(HRZ)3
4HR
4(HR)3
6
6
Category 4 Chronic or suspected MDR-TB cases
Specially designed standardized or individualized regimen
![Page 69: Chemotherapy of Tuberculosis](https://reader034.vdocuments.net/reader034/viewer/2022051518/568155e4550346895dc3ac07/html5/thumbnails/69.jpg)
DOTS plus :- first WHO endorsed DOTS-Plus programmes began in 2000- To treat MDR-TB using
second line anti TB drugs. - Recommended in areas where DOTS is fully in place.
![Page 70: Chemotherapy of Tuberculosis](https://reader034.vdocuments.net/reader034/viewer/2022051518/568155e4550346895dc3ac07/html5/thumbnails/70.jpg)
Five components of DOTS Plus
![Page 71: Chemotherapy of Tuberculosis](https://reader034.vdocuments.net/reader034/viewer/2022051518/568155e4550346895dc3ac07/html5/thumbnails/71.jpg)
![Page 72: Chemotherapy of Tuberculosis](https://reader034.vdocuments.net/reader034/viewer/2022051518/568155e4550346895dc3ac07/html5/thumbnails/72.jpg)
Sustained political and administrative commitment A well functioning DOTS programme. Long term investment of staff and resources. Coordination efforts between community, local
governments, and international agencies. Addressing the factors leading to the
emergence of MDR-TB
![Page 73: Chemotherapy of Tuberculosis](https://reader034.vdocuments.net/reader034/viewer/2022051518/568155e4550346895dc3ac07/html5/thumbnails/73.jpg)
Diagnosis of MDR-TB through quality-assured culture and drug susceptibility testing. Proper triage of patients for Culture & testing
and management under DOTS-Plus. Co-ordination with National and Supra-National
Reference Laboratories
![Page 74: Chemotherapy of Tuberculosis](https://reader034.vdocuments.net/reader034/viewer/2022051518/568155e4550346895dc3ac07/html5/thumbnails/74.jpg)
Appropriate treatment strategies that utilize second-line drugs under proper management conditions
Rational standardized treatment design (evidence-based)
Directly observed therapy (DOT) ensuring long-term adherence.
Monitoring and management of adverse drug reactions.
Adequate human resources.
![Page 75: Chemotherapy of Tuberculosis](https://reader034.vdocuments.net/reader034/viewer/2022051518/568155e4550346895dc3ac07/html5/thumbnails/75.jpg)
TB treatment in HIV patients:Rifabutin preferred over rifampicin
in HIV patients on antiretroviral drugs as it doesn’t interact with PI’s.
![Page 76: Chemotherapy of Tuberculosis](https://reader034.vdocuments.net/reader034/viewer/2022051518/568155e4550346895dc3ac07/html5/thumbnails/76.jpg)
Role of glucocorticoids in tuberculosis
![Page 77: Chemotherapy of Tuberculosis](https://reader034.vdocuments.net/reader034/viewer/2022051518/568155e4550346895dc3ac07/html5/thumbnails/77.jpg)
Tuberculosis is a relative CI for use of glucocorticoids.
![Page 78: Chemotherapy of Tuberculosis](https://reader034.vdocuments.net/reader034/viewer/2022051518/568155e4550346895dc3ac07/html5/thumbnails/78.jpg)
TB of serum membrane like pleura, peritonium, pericardium, meninges, to prevent fibrous tissue formation.
To treat hypersensitivity reactions to antiTB drugs.
Tuberculosis of eye, larynx, genitourinary tract to prevent fibrosis & scar tissue formation.Once patients general condition improves, steroid is tapered to avoid HPA axis suppression.